Form 4: Aura Biosciences CLO Executes Tax-Related Stock Sale

Chief Legal Officer Conor Kilroy sold 11,738 shares of Aura Biosciences to satisfy tax withholding obligations.

Summary

• Conor Kilroy, Chief Legal Officer and Secretary of Aura Biosciences, Inc., sold 11,738 shares of common stock.
• The transaction occurred on April 16, 2026, at a weighted average price of $7.02 per share.
• The sale was executed automatically to cover tax withholding obligations related to the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and non-discretionary.

Positives

• The sale was non-discretionary and mandated by tax obligations, indicating it was not a reflection of management's outlook on the company's future performance.

Negatives

• The transaction resulted in a reduction of the insider's direct beneficial ownership to 217,835 shares.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Management Comments

• The sales reported represent the number of shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice for corporate executives in the biotechnology sector to manage tax liabilities upon the vesting of equity compensation.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance in the U.S. biotech industry.

Stakeholder Impact

• Minimal impact on shareholders as the sale was automatic and related to tax obligations.

Next Steps

• None mentioned.

Key Dates

Keywords

Aura Biosciences, AURA, Insider Trading, Form 4, Tax Withholding, Biotech